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Abstract
Recent WHO guidelines recommend a universal “test and treat” strategy for malaria, mainly by use of rapid
diagnostic test (RDT) in all areas. The evidence for this approach is questioned here as there is a risk of over-
reliance on parasitological diagnosis in high transmission situations, which still exist. In such areas, when a patient
has fever or other malaria symptoms, the presence of Plasmodium spp neither reliably confirms malaria as the
cause of the fever, nor excludes the possibility of other diseases. This is because the patient may be an
asymptomatic carrier of malaria parasites and suffer from another disease.
To allow clinicians to perform their work adequately, local epidemiologic data are necessary. One size does not fit
all. If parasite prevalence in the population is low, a diagnostic test is relevant; if the prevalence is high, the test
does not provide information of any clinical usefulness, as happens with any test in medicine when the prevalence
of the tested characteristic is high in the healthy population. It should also be remembered that, if in some cases
anti-malarials are prescribed to parasite-negative patients, this will not increase selection pressure for drug
resistance, because the parasite is not there.
In high transmission situations at least, other diagnoses should be sought in all patients, irrespective of the
presence of malaria parasites. For this, clinical skills (but not necessarily physicians) are irreplaceable, in order to
differentiate malaria from other causes of acute fever, such as benign viral infection or potentially dangerous
conditions, which can all be present with the parasite co-existing only as a “commensal” or silent undesirable
guest.
Background
The latest WHO guidelines on the treatment of malaria
state that, whenever possible, “in all settings, clinical
suspicion of malaria should be confirmed with a parasi-
tological diagnosis“ [1,2]. This is a significant change
from the previous guidelines [3], which recognized that
parasitological diagnosis is not always necessary, particu-
larly in high transmission areas. This new universal “test
and treat” recommendation is based on a series of ques-
tionable assumptions (Table 1) [1]. The question of
whether to test and treat or to treat presumptively is
still hotly debated [4,5].
WHO’s assumptions are discussed one by one, con-
sidering their applicability to high-transmission
settings, which still exist. Basically, the « level of trans-
mission » in malarial areas is an entomological con-
cept. In most cases, the so-called transmission level is
derived from the proportion of infected people in the
general population. For practical purposes, it is consid-
ered here that « low transmission » is characteristic of
areas where this proportion in the general population
is below 20%. Between 20 and 50%, one can speak of «
moderate transmission » and « high » above 50%.
Since there is no universal definition, or cut-off figures,
for “high-transmission”, the discussion below will detail
at what levels of parasite prevalence in the population
a parasitological test supports, or does not support,
clinical decisions.
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Assumption 1: “diagnosis based on clinical features alone
has very low specificity and results in over-treatment“
The specificity of a diagnostic algorithm or test almost
always varies according to the prevalence of the target
condition. Clinical diagnosis and parasitological tests for
malaria are no exception. The specificity of clinical diag-
nosis of malaria varies according to age group, time,
place and the epidemiology of the disease. In low-trans-
mission settings, specificity of clinical diagnosis is low
and specificity of parasitological tests (e.g. rapid diagnos-
tic tests - RDTs) is high, whereas in high-transmission
areas the reverse is the case[6]. In children in a high-
transmission setting, during the rainy season, high fever
of short duration, with no other obvious cause, is most
likely to be malaria [7]. In some such settings over 80%
of febrile patients (all ages) with presumed malaria are
parasite positive, and the “test and treat” strategy is not
cost-effective, particularly in children and where the
cost of treatment is lower than that of the test [8,9].
Assumption 2: “patient care will be improved in parasite-
positive patients“
This assumption is incorrect, particularly in high trans-
mission areas. In a randomized controlled trial (in Bur-
kina Faso in 2006), comparing outcomes in patients
treated either presumptively or after use of an RDT,
there was no difference in outcomes between groups
[ 1 0 ] ,i . e .t h eu s eo fR D Td i dn o ti m p r o v ec a r ei nt h i s
setting. The more prevalent a characteristic is in the
healthy population, the less useful it is to test for this
characteristic as a means of detecting disease.
A useful tool for evaluating the clinical utility of a test
is to calculate the likelihood ratio of having a disease,
based on a positive or a negative result. The likelihood
ratio multiplied by the pre-test odds of the disease gives
the post-test odds. Figures 1, and 2 show how pre- and
post-test probability of malaria infection for a negative
and a positive test result change according to the back-
ground prevalence of infection with malaria parasites
and the sensitivity of the test, 95% in Figure 1 and 85%
in Figure 2 (based on statistical modelling[11]). The 85%
sensitivity might be closer to what happens when the
test has been stored in relatively hot conditions [12].
In summary, where the prevalence of malaria infection
is low, a parasitological test is useful: if it is negative,
the post-test probability of malaria is almost zero. If the
test is positive, the probability of malaria is greatly
increased. However at higher levels of prevalence, a
negative test does not rule out infection with malaria
parasites, and a positive test does not greatly increase
the probability of malaria infection (which is already
Table 1 Advantages and disadvantages of parasitological diagnosis
Advantages of parasitological diagnosis (according to WHO
guidelines, section 6.1, 6.2)
Disadvantages of parasitological diagnosis in high transmission
areas
Diagnosis based on clinical features alone has very low specificity and
results in over-treatment
Parasitological diagnosis has low specificity
Improved patient care in parasite-positive patients In a patient with fever, the presence of parasites neither reliably confirms
malaria as the cause of the fever, nor excludes the possibility of other
diseases
Identification of parasite-negative patients in whom another diagnosis
must be sought
Other diagnoses should be sought in all patients, irrespective of the
presence of malaria parasites
Prevention of unnecessary use of anti-malarials, reducing frequency of
adverse effects especially in those who do not need the medicines, and
drug pressure selecting for resistant parasites
Clinicians often prescribe anti-malarials even for patients with a negative
test. Prescribing anti-malarials to parasite-negative patients will not
increase selection pressure for new drug resistant mutations.
Improved malaria case detection and reporting Some “cases” detected in high-transmission areas are incidental carriers
of malaria parasites, presenting with another disease
Confirmation of treatment failures RDTs cannot confirm treatment failures. It is only possible to do this with
microscopy.
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Figure 1 Pre-test and post-test probability of infection with
malaria parasites for patients with a positive or negative test
result, in areas of differing malaria prevalence, assuming a
sensitivity and a specificity of the test of 95%. (Data from[11])
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Page 2 of 8high). There is no clear threshold for applying a cut-off,
but one commonly used rule is that a test is clinically
useful to “rule in” or “rule out” a disease if the positive
l i k e l i h o o dr a t i oi s>=5 ,o ri f the negative likelihood
ratio is < = 0.2 respectively[13]. Applying this rule, a
positive test ceases to be clinically useful at a prevalence
of > 20% (see figure 3).
Parasite prevalence has declined in some parts of
A f r i c a ,b u tt h em e d i a ni narecent review is still 22%
[14]. Of note this review did not include any studies
from rural West Africa after 2000, and excluded com-
munity-based studies. Table 2 shows the prevalence of
malaria in populations where diagnostic tests have been
deployed since 2005. The weighted overall mean parasite
prevalence ( = pre-test probability) was 51.7% (of 87 703
patients tested). Populations develop partial immunity
against malaria by the age of five years and in such
semi-immune individuals even high levels of parasite
density do not reliably predict fever incidence [15].
In a patient with fever (or other malaria symptoms) in
a high-transmission area, the presence of parasites
neither reliably confirms malaria as the cause, nor
excludes the possibility of other diseases [9]. Like many
commensal organisms, P. falciparum can produce symp-
toms, but may also be asymptomatic (it may, however,
have undesirable effects in the long run). Detecting the
presence of parasites can be misleading. It may divert
the attention of clinicians from other diagnoses if they
do not conduct an appropriate clinical examination. For
example, the case of an infant is reported with a positive
malaria test who was only treated with anti-malarials
b u ts u b s e q u e n t l yd i e do fp r e s u m e dp n e u m o n i a [ 1 0 ] .
Paradoxically the care of parasite-positive patients may
worsen through over-reliance on diagnostic tests at the
expense of clinical examination [4].
Assumption 3: “identification of parasite-negative patients
in whom another diagnosis must be sought“
In high transmission areas, other diagnoses should be
sought in all patients, irrespective of the presence of
malaria parasites. Some analyses assume that there is no
co-infection between malarial and bacterial infections
[16], but this assumption is clearly incorrect. For exam-
ple 14% of unconscious children aged < 1 year present-
ing to Kilifi hospital in Kenya had both malaria parasites
and definite bacterial meningitis[17]. Therefore in sec-
ondary care settings (in high-transmission areas), in chil-
dren presenting with serious febrile illness, bacterial
illness should be considered regardless of parasitological
test results [18].
However it is inappropriate to extrapolate findings
from severely ill children in secondary care settings, to
children with uncomplicated febrile illness in primary
care settings[5], which are the majority of the cases in
which parasitological tests have been used (Table 2). A
parasite-negative child with uncomplicated febrile illness
is not at high risk of other life-threatening bacterial dis-
eases, and the most common other diagnosis is viral
upper-respiratory tract infection [9,19]. Unless other
clinical features of a bacterial infection are present, anti-
biotics are not indicated.
Antibiotics should not be overused in primary care
settings, otherwise there is a higher risk of evolution
and spread of resistant bacteria (because all human
beings harbour commensal bacteria which can evolve
resistance to antibiotics, and become pathogenic). Some
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Figure 2 Pre-test and post-test probability of infection with
malaria parasites for patients with a positive or negative test
result, in areas of differing malaria prevalence, assuming a
sensitivity of 85% and a specificity of the test of 95%. (Data
from[11])
Figure 3 Likelihood ratios of malaria when the parasite
detection test is positive (LR+) and likelihood ratios of the
absence of malaria when the parasite detection test is
negative (LR -), according to the prevalence of infection in the
general population, and to the sensitivity and specificity of the
test for the detection of parasites. Clinically useful tests are above
the line (LR > 5). (Data from [11])
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scribing in malaria-negative patients [20,21] (Table 2). If
the disease is a common cold, antibiotics should gener-
ally be avoided. For example, in hospital outpatients in
Tanzania, 74% of children aged < 5 years with a negative
malaria test were prescribed an antibiotic[22]. This is
not necessarily an indicator of good practice. In another
trial, this time in Uganda, 45% of children with upper
respiratory tract infections and common colds were pre-
scribed an antibiotic [19]. The need for antibiotics or
Table 2 Prescribing behaviour of clinicians for parasite-negative patients in different contexts, 2005-2010
% of parasite-negative
patients receiving any
antimalarial
Total N of
parasite-
neg pts
% of parasite-
negative patients
receiving antibiotics
Diagnostic
test
Country Setting Transmission
level
% of patients
positive for
malaria
Year
of
study
Ref
4.0% 5162 35.6% RDT Tanzania Rural Health
Centres
high 51.5% 2008 [28]
9.0% 14777 Microscopy
and RDT
Uganda District
hospital
outpatients
high 45.0% 2010 [29]
11.7% 700 45.0% RDT Zanzibar Primary
Health Care
high 30.0% 2005 [21]
27.0% 247 50.0% Microscopy Tanzania Hospital
Outpatients
high 38.4% 2005 [22]
30.0% 218 50.0% RDT Tanzania Hospital
Outpatients
high 38.4% 2005 [22]
31.8% 4661 RDT Uganda Primary
Health Care
Low - high 625% 2007 [39]
35.5% 183 RDT Zambia Outpatients,
rural and
urban
high 44.2% 2006 [30]
36.0% 392 RDT Kenya Government
health
facilities
Low - high 12% 2006 [40]
40.4% 141 55.3% RDT Tanzania Hospital
Outpatients
high 55.4% 2006 [41]
46.0% 1298 28.8% RDT Ghana Rural health
centres
high 26.2% 2007-
2008
[20]
49.5% 1013 35.0% RDT Ghana Rural health
centres
high 37.7% 2007-
2008
[20]
49.5% 1325 28.6% Microscopy Ghana Rural health
centres
high 26.9% 2007-
2008
[20]
54.6% 416 50.0% Microscopy Tanzania Hospital
Outpatients
low 0.4% 2005 [22]
58.0% 401 50.0% RDT Tanzania Hospital
Outpatients
low 0.4% 2005 [22]
58.4% 77 Microscopy Zambia Outpatients,
rural and
urban
high 45.4% 2006 [30]
61.3% 68 87.1% RDT/
microscopy
Kenya Outpatients
> = 5 years
high 52.7% 2006 [42]
63.0% 367 50.0% Microscopy Tanzania Hospital
Outpatients
low-moderate 8.3% 2005 [22]
63.0% 386 50.0% RDT Tanzania Hospital
Outpatients
low-moderate 8.3% 2005 [22]
75.0% 52 84.6% RDT/
microscopy
Kenya Outpatients
< 5 yrs
high 50.0% 2006 [42]
79.8% 287 54.7% RDT Burkina
Faso
Primary care,
rural, dry
season
low 28.2% 2006 [10]
82.6% 206 59.9% RDT Burkina
Faso
Primary care,
rural, rainy
season
high 68.2% 2006 [10]
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tory and examination, not by the presence or absence of
malaria parasites. Key for this is the local quality of clin-
ical work and teaching. Indeed there is an interesting
parallel between the decision to prescribe anti-malarials
and the decision to prescribe antibiotics for chest infec-
tions. The latter is often based on presumptive diagnosis
from clinical features [23], and a “bacterial test” would
be of dubious utility because there are many healthy
carriers.
The utility of a negative result also depends on the
sensitivity of the test [11] (see Figures 1-2). In practice,
sensitivity of RDTs varies widely according to setting
[12] and brand[24]. Although some studies have shown
excellent sensitivity[25], others have shown that sensitiv-
ity is much lower in field conditions[12]; this can be due
to storage temperatures above 30 degree Celsius, for
example. Sensitivity of RDTs is lower for low levels of
parasitaemia[9,26]. These are irrelevant in semi-immune
patients (age > 5 years in high-transmission settings)
and so in these patients it is safe not to treat RDT-nega-
tive patients with anti-malarials[27]. However in non-
immune infants even very low parasitaemia cause dis-
e a s ea n dm a n yo ft h e s ea r em i s s e db yR D T s ,w h i c hi s
particularly important in high transmission situations
[26]. Of course, the sensitivity of clinical diagnosis varies
as well, but in a high-transmission setting presumptive
treatment of all febrile infants with anti-malarials is
probably safer than relying on the result of an RDT[26].
Assumption 4: “prevention of unnecessary use of anti-
malarials, reducing frequency of adverse effects, especially
in those who do not need the medicines, and drug pressure
selecting for resistant parasites“
Many studies found that diagnostic testing did not pre-
vent the use of anti-malarials for patients in whom no
parasites are detected. Table 2 summarizes studies of
prescriptions for parasite-negative patients since 2005.
The two largest and most recent studies in Tanzania
and Uganda found that only 4% and 9% of parasite-
negative patients were prescribed anti-malarials,
although in Tanzania the test-and-treat strategy was
only used for patients aged 5 years and older [28,29].
Other studies found that much larger proportions of
malaria-negative patients still received anti-malarials.
The weighted mean of all the studies (for a total of
87703 patients) was that 23.3% of parasite-negative
patients received a prescription for anti-malarials. In
summary, the use of RDTs reduced prescribing of anti-
malarials in some studies [21,28-30] but in several cases,
using RDTs significantly increased costs to the health
service provider[31]. In no case was there any evidence
of clinical benefit to patients or of improved cost-effec-
tiveness. The argument that treating malaria-negative
patients will increase the drug pressure for resistant
parasites seems logically incoherent because malaria-
negative patients harbour no parasites. Long-acting
drugs given together with artemisinin derivatives have a
long, slow tail phase of drug elimination, during which
time new infections may be acquired. Parasites which
already have resistance to these drugs may be selected
for, but it is improbable that any new resistant muta-
tions would develop in this context because the biomass
of parasites in the inoculum is low. A strategy for pre-
venting resistance could be to keep ACTs for patients at
highest risk of severe malaria (non-immune patients)
and to use other medicines for semi-immune patients
(aged 5 years and older, in high-transmission areas),
who will improve with other treatments[32].
Assumption 5: “improved malaria case detection and
reporting“
Parasitological diagnosis will enable health information
systems to report more accurately whether patients con-
sulting with fever or treated for malaria actually had evi-
dence of being parasitaemic. For example, in Senegal,
there has been a large decrease in reported malaria
cases, in part due to better case ascertainment with
RDTs [30]. However, it is not clear whether this advan-
tage alone justifies the extra expense of systematically
making a parasitological diagnosis. Regular population
studies might be more appropriate for health informa-
tion and policy design.
While case detection may be improved in low-trans-
mission areas, in high-transmission areas what will often
be detected and reported is incidental parasitaemia (the
presence of malaria parasites in a patient presenting
symptoms not attributable to the malaria parasite)
rather than clinical malaria. A more useful measure is
the population attributable fraction of fever due to
malaria[26]. Furthermore, since the results may vary
considerably in the same individual on the same day,
the usual single blood test to determine the presence or
absence of parasites may be misleading [33,34]. In short,
parasitological diagnosis does not mean case detection,
because of the importance of carriers who are not cases.
However, RDTs may well be the tool of choice for rapid
assessment of local epidemiology.
Assumption 6: “Confirmation of treatment failures”
Rapid diagnostic tests based on detection of the HRP-2
antigen often remain positive for over five weeks after
the disappearance of live parasites, because they detect
the HRP-2 antigen which is still present in debris from
dead parasites for some time after total parasite clear-
ance [35]. This also results in a high “false positive rate”
and low specificity of RDTs compared to microscopy,
particularly in high transmission areas [6,36]. If RDTs
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will be given a second unnecessary treatment.
Microscopy does not help to confirm treatment failure
unless it is of excellent quality, which is rare outside of
research settings. In such settings, when high-quality
microscopy is available, a negative film is very good at
detecting the absence of malaria parasites in the blood
(Figure 4) and it is unusual for a patient with a negative
blood film (made and read according to a high quality
protocol, with double or triple readings of every slide)
to subsequently develop malaria [19]. However, it is
rarely possible to sustain such high quality microscopy
outside the research setting, and poor quality micro-
scopy is not clinically useful [37,38] for confirmation of
treatment failures.
Discussion
From the review of the evidence above it seems that a
universal “test and treat” strategy is neither evidence-
based nor cost-effective. The new WHO guidelines can
be understood in the context of the long term goal of
elimination of malaria. However, this is not achievable
in the foreseeable future in many areas. WHO’s assump-
tions justifying parasitological diagnosis may well be
correct in low-transmission settings, but not in high-
transmission settings. The prevalence of malaria parasi-
taemia has declined in some parts of Africa, so these
areas are transitioning from high-transmission to low-
transmission. In these areas, diagnostic tests will become
increasingly important. However, many areas of sub-
Saharan Africa remain high-transmission areas, and the
appropriateness and cost-effectiveness of universal test-
ing in these areas is questionable.
Malaria is a complex disease and it is impossible to
write clinically useful global guidelines on its manage-
ment, which do not take local epidemiology into account.
In practice countries contain areas with differing levels of
transmission, which also depends on seasonality. It
would make more sense to adapt the strategy according
to local factors. This is the way health professionals deal
with any infectious disease (evaluating the probability of
a particular disease case by case, according to season,
age, place of residence, recent travel, and so on). It is per-
fectly possible to apply two different policies simulta-
neously (for example presumptive treatment for patients
aged < 5 years and test-and-treat for older patients)[28].
Even where such a policy does not formally exist, health
workers are more likely to prescribe anti-malarials for
RDT-negative patients aged < 5 years than for those aged
5 years and over[39]. If health care workers are able to do
better than blindly applying global guidelines, this should
not be considered “second class” treatment. The level of
skill required to identify serious infection, malaria and
‘trivial’ viral infection is probably achieved through stan-
dard medical training in most countries, but it remains to
be seen to what extent it is also achievable for shorter
training in other health professions.
If the WHO recommendations have little influence on
clinical practice, this may not be due solely to problems
of policy implementation, but also to the fact that the
debate has been closed too early[1]. Those clinicians
using their clinical skills and not following the recom-
mended “test and treat strategy” in high transmission
areas do not increase the danger for their patients nor
jeopardize the future of the malaria global strategy.
They may well act this way not against their will or
because of logistical problems or lack of information.
The reliance on clinical skills and “bedside reasoning”,
based on, among others, the knowledge of local epide-
miology, makes good sense in the clinical encounter.
The presumptive treatment strategy for malaria could
be in the best interest of some patients, now and in the
future, at least in high-transmission areas where eradica-
tion is not in sight.
Figure 4 Fagnan Sanogo performs microscopy for malaria
parasites in a research clinic in Mali. High-quality microscopy is
rarely sustained outside the research setting (Photo by M. Willcox).
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eration especially in settings where health care resources
are limited. In settings of high transmission the cost sav-
ing from avoiding ACT is outweighed by the greater cost
of deploying RDTs universally [9,31]. RDTs are not cost-
effective even in low-transmission areas, unless adher-
ence to their results is high [8]. Even where the adher-
ence is relatively good there is no clear evidence of any
clinical benefit[20]. There may be higher priorities for
limited resources than universal parasitological diagnosis.
Conclusion
There is a need for policies and clinical strategies
adapted to different settings. Each area should develop
its own guidelines based on sound evidence, taking into
consideration both the local epidemiology of malaria
and other febrile diseases and a realistic assessment of
available healthcare resources. It would be a dangerous
mistake to rely too much on diagnostic tests in areas
where parasite prevalence is high. Clinical examination
and reasoning remain necessary in order to differentiate
malaria from other causes of acute disease such as
benign viral infection or potentially dangerous condi-
tions (which can all be present with the parasite co-
existing only as a commensal or undesirable guest). To
allow clinicians to perform their work adequately, local
epidemiological data are necessary: in areas of low para-
site prevalence, a diagnostic test is relevant; if the preva-
lence is high, the test does not provide information of
any clinical usefulness. In this latter case, clinical skills
are irreplaceable.
Consent
Written informed consent was obtained from all indivi-
duals for publication of accompanying images.
Acknowledgements
Liesl Graz for help in preparing this manuscript.
Author details
1Institute of Social and Preventive Medicine, University of Geneva,
Switzerland.
2Department of Primary Health Care, University of Oxford, UK.
Authors’ contributions
BG and AR wrote a first draft of the article which was substantially revised
by MW and TS. All authors read and approved the final manuscript.
Conflict of interest
The authors declare that they have no competing interests.
Received: 13 January 2011 Accepted: 20 May 2011
Published: 20 May 2011
References
1. WHO: Guidelines for the treatment of malaria (2e). Geneva: World Health
Organisation;, 2 2010.
2. Zarocostas J: Malaria treatment should begin with parasitological
diagnosis where possible, says WHO. BMJ 2010, 340:c1402.
3. WHO: Guidelines for the treatment of malaria. Geneva: WHO; 2006.
4. English M, Reyburn H, Goodman C, Snow RW, English M, Reyburn H,
Goodman C, Snow RW: Abandoning presumptive antimalarial treatment
for febrile children aged less than five years–a case of running before
we can walk? PLoS Medicine/Public Library of Science 2009, 6:e1000015.
5. D’Acremont V, Lengeler C, Mshinda H, Mtasiwa D, Tanner M, Genton B:
Time to move from presumptive malaria treatment to laboratory-
confirmed diagnosis and treatment in African children with fever. PLoS
Medicine/Public Library of Science 2009, 6:e252.
6. Kyabayinze DJ, Tibenderana JK, Odong GW, Rwakimari JB, Counihan H:
Operational accuracy and comparative persistent antigenicity of HRP2
rapid diagnostic tests for Plasmodium falciparum malaria in a
hyperendemic region of Uganda. Malaria Journal 2008, 7:221.
7. Rougemont A, Breslow N, Brenner E, Moret AL, Dumbo O, Dolo A, Soula G,
Perrin L: Epidemiological basis for clinical diagnosis of childhood malaria
in endemic zone in West Africa. Lancet 1991, 338:1292-1295.
8. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya S, Whitty CJM, Mills A:
The impact of response to the results of diagnostic tests for malaria:
cost-benefit analysis. BMJ 2008, 336:202-205.
9. Willcox ML, Sanogo F, Graz B, Forster M, Dakouo F, Sidibe O, Falquet J,
Giani S, Diakite C, Diallo D: Rapid diagnostic tests for the home-based
management of malaria, in a high-transmission area. Annals of Tropical
Medicine & Parasitology 2009, 103:3-16.
10. Bisoffi Z, Sirima BS, Angheben A, Lodesani C, Gobbi F, Tinto H, Vanden
Ende J: Rapid malaria diagnostic tests vs. clinical management of malaria
in rural Burkina Faso: safety and effect on clinical decisions. A
randomized trial. Tropical Medicine & International Health 2009, 14:491-498.
11. Perneger TV, Szeless T, Rougemont A: Utility of the detection of
Plasmodium parasites for the diagnosis of malaria in endemic areas.
BMC Infectious Diseases 2006, 6:81.
12. Cheng A, Bell D: Evidence behind the WHO guidelines: hospital care for
children: what is the precision of rapid diagnostic tests for malaria? J
Trop Pediatr 2006, 52:386-389.
13. Vanden Bruel A, Haj-Hassan T, Thompson M, Buntinx F, Mant D: Diagnostic
value of clinical features at presentation to identify serious infection in
children in developed countries: a systematic review. Lancet 2010,
375:834-845.
14. D’Acremont V, Lengeler C, Genton B: Reduction in the proportion of
fevers associated with Plasmodium falciparum parasitaemia in Africa: a
systematic review. Malar J 2010, 9:240.
15. Bouvier P, Rougemont A, Breslow N, Doumbo O, Delley V, Dicko A,
Diakite M, Mauris A, Robert CF: Seasonality and malaria in a west African
village: does high parasite density predict fever incidence? American
Journal of Epidemiology 1997, 145:850-857.
16. Shillcutt S, Morel C, Goodman C, Coleman P, Bell D, Whitty CJ, Mills A: Cost-
effectiveness of malaria diagnostic methods in sub-Saharan Africa in an
era of combination therapy. Bulletin of the World Health Organization 2008,
86:101-110.
17. Berkley JA, Mwangi I, Mellington F, Mwarumba S, Marsh K: Cerebral malaria
versus bacterial meningitis in children with impaired consciousness. QJM
1999, 92:151-157.
18. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O,
Saganda K, Shao J, Kitua A, Olomi R, et al: Overdiagnosis of malaria in
patients with severe febrile illness in Tanzania: a prospective study. BMJ
2004, 329:1212.
19. Njama-Meya D, Clark TD, Nzarubara B, Staedke S, Kamya MR, Dorsey G:
Treatment of malaria restricted to laboratory-confirmed cases: a
prospective cohort study in Ugandan children. Malaria Journal 2007, 6:7.
20. Ansah EK, Narh-Bana S, Epokor M, Akanpigbiam S, Quartey AA, Gyapong J,
Whitty CJM: Rapid testing for malaria in settings where microscopy is
available and peripheral clinics where only presumptive treatment is
available: a randomised controlled trial in Ghana. BMJ 2010, 340:c930.
21. Msellem MI, Martensson A, Rotllant G, Bhattarai A, Stromberg J, Kahigwa E,
Garcia M, Petzold M, Olumese P, Ali A, Bjorkman A: Influence of rapid
malaria diagnostic tests on treatment and health outcome in fever
patients, Zanzibar: a crossover validation study. PLoS Medicine/Public
Library of Science 2009, 6:e1000070.
22. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C,
Whitty CJM: Rapid diagnostic tests compared with malaria microscopy
for guiding outpatient treatment of febrile illness in Tanzania:
randomised trial. BMJ 2007, 334:403.
Graz et al. Malaria Journal 2011, 10:136
http://www.malariajournal.com/content/10/1/136
Page 7 of 823. WHO: Management of the child with a serious infection or severe
malnutrition. Geneva: WHO; 2000.
24. WHO, FIND, CDC, TDR: Malaria rapid diagnostic test performance: results
of WHO product testing malaria RDTs: round 2 (2009). Geneva: World
Health Organisation; 2010.
25. Singh N, Saxena A: Usefulness of a rapid on-site Plasmodium falciparum
diagnosis (Paracheck PF) in forest migrants and among the indigenous
population at the site of their occupational activities in central India. Am
J Trop Med Hyg 2005, 72:26-29.
26. Bisoffi Z, Sirima S, Menten J, Pattaro C, Angheben A, Gobbi F, Tinto H,
Lodesani C, Neya B, Gobbo M, Vanden Ende J: Accuracy of a rapid
diagnostic test on the diagnosis of malaria infection and of malaria -
attributable fever during low and high transmission season in Burkina
Faso. Malaria Journal 2010, 9:192.
27. D’Acremont V, Malila A, Swai N, Tillya R, Kahama-Maro J, Lengeler C,
Genton B: Withholding antimalarials in febrile children who have a
negative result for a rapid diagnostic test. Clin Infect Dis 2010, 51:506-511.
28. Masanja MI, McMorrow M, Kahigwa E, Kachur SP, McElroy PD: Health
workers’ use of malaria rapid diagnostic tests (RDTs) to guide clinical
decision making in rural dispensaries, Tanzania. Am J Trop Med Hyg 2010,
83:1238-1241.
29. Sserwanga A, Harris JC, Kigozi R, Menon M, Bukirwa H, Gasasira A,
Kakeeto S, Kizito F, Quinto E, Rubahika D, et al: Improved Malaria Case
Management through the Implementation of a Health Facility-Based
Sentinel Site Surveillance System in Uganda. PLoS ONE 2011, 6:e16316.
30. WHO: Parasitological confirmation of malaria diagnosis: WHO technical
consultation, Geneva, 6-8 October 2009. Geneva: World Health
Organisation; 2010.
31. Yukich J, D’Acremont V, Kahama J, Swai N, Lengeler C: Cost savings with
rapid diagnostic tests for malaria in low-transmission areas: evidence
from Dar es Salaam, Tanzania. Am J Trop Med Hyg 2010, 83:61-68.
32. Graz B, Willcox M, Diakite C, Falquet J, Dakouo F, Sidibe O, Giani S, Diallo D:
Argemone mexicana decoction versus Artesunate/Amodiaquine for the
home-based management of malaria in Mali. Policy and public health
implications. Transactions of the Royal Society of Tropical Medicine & Hygiene
2010, 104:33-41.
33. Delley V, Bouvier P, Breslow N, Doumbo O, Sagara I, Diakite M, Mauris A,
Dolo A, Rougemont A: What does a single determination of malaria
parasite density mean? A longitudinal survey in Mali. Tropical Medicine &
International Health 2000, 5:404-412.
34. Szeless T: De l’infection à la maladie, un processus mal connu: l’exemple
du paludisme dans une zone endémique d’Afrique sub-saharienne.
University of Geneva, Department of Medicine; 2009.
35. Swarthout TD, Counihan H, Senga RK, van den Broek I, Swarthout TD,
Counihan H, Senga RKK, van den Broek I: Paracheck-Pf accuracy and
recently treated Plasmodium falciparum infections: is there a risk of
over-diagnosis? Malaria Journal 2007, 6:58.
36. Abeku TA, Kristan M, Jones C, Beard J, Mueller DH, Okia M, Rapuoda B,
Greenwood B, Cox J: Determinants of the accuracy of rapid diagnostic
tests in malaria case management: evidence from low and moderate
transmission settings in the East African highlands. Malaria Journal 2008,
7:202.
37. McMorrow ML, Masanja MI, Abdulla SMK, Kahigwa E, Kachur SP: Challenges
in routine implementation and quality control of rapid diagnostic tests
for malaria–Rufiji District, Tanzania. American Journal of Tropical Medicine
& Hygiene 2008, 79:385-390.
38. Zurovac D, Larson BA, Skarbinski J, Slutsker L, Snow RW, Hamel MJ,
Zurovac D, Larson BA, Skarbinski J, Slutsker L, et al: Modeling the financial
and clinical implications of malaria rapid diagnostic tests in the case-
management of older children and adults in Kenya. American Journal of
Tropical Medicine & Hygiene 2008, 78:884-891.
39. Kyabayinze D, Asiimwe C, Nakanjako D, Nabakooza J, Counihan H,
Tibenderana J: Use of RDTs to improve malaria diagnosis and fever case
management at primary health care facilities in Uganda. Malaria Journal
2010, 9:200.
40. Skarbinski J, Ouma PO, Causer LM, Kariuki SK, Barnwell JW, Alaii JA, de
Oliveira AM, Zurovac D, Larson BA, Snow RW, et al: Effect of Malaria Rapid
Diagnostic Tests on the Management of Uncomplicated Malaria with
Artemether-Lumefantrine in Kenya: A Cluster Randomized Trial. Am J
Trop Med Hyg 2009, 80:919-926.
41. Chandler CIR, Chonya S, Boniface G, Juma K, Reyburn H, Whitty CJM: The
importance of context in malaria diagnosis and treatment decisions - a
quantitative analysis of observed clinical encounters in Tanzania. Tropical
Medicine & International Health 2008, 13:1131-1142.
42. Zurovac D, Njogu J, Akhwale W, Hamer DH, Larson BA, Snow RW: Effects of
revised diagnostic recommendations on malaria treatment practices
across age groups in Kenya. Tropical Medicine & International Health 2008,
13:784-787.
doi:10.1186/1475-2875-10-136
Cite this article as: Graz et al.: “Test and treat” or presumptive
treatment for malaria in high transmission situations? A reflection on
the latest WHO guidelines. Malaria Journal 2011 10:136.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Graz et al. Malaria Journal 2011, 10:136
http://www.malariajournal.com/content/10/1/136
Page 8 of 8